Header Logo

Ruiwen Zhang

TitleProfessor
InstitutionUniversity of Houston
DepartmentPharmacological and Pharmaceutical Sciences
Address4800 Calhoun Rd
Houston TX 77004
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    R01CA214019     (ZHANG, RUIWEN)Sep 4, 2017 - Aug 31, 2022
    NIH
    Novel NFAT1-MDM2 inhibitor for Breast Cancer Therapy
    Role: Principal Investigator
    R01CA186662     (ZHANG, RUIWEN)Apr 1, 2014 - Feb 28, 2021
    NIH
    Novel Small Molecule MDM2 Inhibitors for Pancreatic Cancer Therapy
    Role: Principal Investigator
    R01CA121211     (ZHANG, RUIWEN)Aug 1, 2007 - May 31, 2014
    NIH
    Dietary Chemopreventive Components/Oncogene Interaction and Cancer
    Role: Principal Investigator
    R01CA112029     (ZHANG, RUIWEN)Jan 1, 2005 - Aug 31, 2014
    NIH
    MDM2 AS A NEGATIVE REGULATOR OF P21 WAF1/CIP1
    Role: Principal Investigator
    R01CA080698     (ZHANG, RUIWEN)Apr 7, 1999 - Mar 31, 2004
    NIH
    MDM2 ONCOGENE AS A TARGET FOR MODULATING CANCER THERAPY
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wang W, Aguilar M, Datta S, Alley A, Tadesse M, Wang X, Gao X, Zhang R. Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: in vitro and in vivo anticancer activities and newly discovered effects on cancer metabolic pathways. Front Pharmacol. 2025; 16:1531667. PMID: 40046748; PMCID: PMC11879958.
      Citations:    
    2. Zhang R. Future Cancer Drug Discovery Is Now. Curr Cancer Drug Targets. 2025; 25(1):1-2. PMID: 39882701.
      Citations:    Fields:    
    3. Wang W, Albadari N, Du Y, Fowler JF, Sang HT, Xian W, McKeon F, Li W, Zhou J, Zhang R. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024 May 02; 76(3):414-453. PMID: 38697854; PMCID: PMC11068841.
      Citations: 8     Fields:    Translation:HumansAnimals
    4. Wang W, Du Y, Datta S, Fowler JF, Sang HT, Albadari N, Li W, Foster J, Zhang R. Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable? Genes Dis. 2025 Mar; 12(2):101156. PMID: 39802403; PMCID: PMC11719324.
      Citations:    
    5. Terrell JR, Tang S, Faniyi OO, Jeong IH, Yin J, Nijampatnam B, Velu SE, Wang W, Zhang R, Luo M. Structural studies of antitumor compounds that target the RING domain of MDM2. Protein Sci. 2022 Aug; 31(8):e4367. PMID: 35900024; PMCID: PMC9301682.
      Citations: 2     Fields:    Translation:AnimalsCells
    6. Kaluz S, Zhang Q, Kuranaga Y, Yang H, Osuka S, Bhattacharya D, Devi NS, Mun J, Wang W, Zhang R, Goodman MM, Grossniklaus HE, Van Meir EG. Targeting HIF-activated collagen prolyl 4-hydroxylase expression disrupts collagen deposition and blocks primary and metastatic uveal melanoma growth. Oncogene. 2021 Aug; 40(33):5182-5191. PMID: 34218269; PMCID: PMC8887959.
      Citations: 9     Fields:    
    7. Zu Y, Zhao L, Hao L, Mechref Y, Zabet-Moghaddam M, Keyel PA, Abbasi M, Wu D, Dawson JA, Zhang R, Nie S, Moustaid-Moussa N, Kolonin MG, Daquinag AC, Brandi L, Warraich I, San Francisco SK, Sun X, Fan Z, Wang S. Browning white adipose tissue using adipose stromal cell-targeted resveratrol-loaded nanoparticles for combating obesity. J Control Release. 2021 May 10; 333:339-351. PMID: 33766692; PMCID: PMC8396108.
      Citations: 10     Fields:    Translation:AnimalsCells
    8. Ibrahim Al-Obaide MA, Arutla V, Bacolod MD, Wang W, Zhang R, Srivenugopal KS. Genomic Space of MGMT in Human Glioma Revisited: Novel Motifs, Regulatory RNAs, NRF1, 2, and CTCF Involvement in Gene Expression. Int J Mol Sci. 2021 Mar 02; 22(5). PMID: 33801310; PMCID: PMC7958331.
      Citations: 4     Fields:    Translation:HumansCells
    9. Wang W, Wang X, Rajaei M, Youn JY, Zafar A, Deokar H, Buolamwini JK, Yang J, Foster JH, Zhou J, Zhang R. Targeting MDM2 for Neuroblastoma Therapy: In Vitro and In Vivo Anticancer Activity and Mechanism of Action. Cancers (Basel). 2020 Dec 05; 12(12). PMID: 33291373; PMCID: PMC7762001.
      Citations: 7     
    10. Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F, Foster J, Zhou J, Zhang R. Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev. 2021 03; 41(2):961-1021. PMID: 33155698; PMCID: PMC7906923.
      Citations: 140     Fields:    Translation:HumansCells
    11. Zafar A, Wang W, Liu G, Xian W, McKeon F, Zhou J, Zhang R. Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope. Cancer Lett. 2021 01 01; 496:16-29. PMID: 33007410; PMCID: PMC8351219.
      Citations: 49     Fields:    Translation:HumansAnimals
    12. Ashraf-Uz-Zaman M, Shahi S, Akwii R, Sajib MS, Farshbaf MJ, Kallem RR, Putnam W, Wang W, Zhang R, Alvina K, Trippier PC, Mikelis CM, German NA. Design, synthesis and structure-activity relationship study of novel urea compounds as FGFR1 inhibitors to treat metastatic triple-negative breast cancer. Eur J Med Chem. 2021 Jan 01; 209:112866. PMID: 33039722; PMCID: PMC7744370.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    13. Cui J, Shu C, Xu J, Chen D, Li J, Ding K, Chen M, Li A, He J, Shu Y, Yang L, Zhang R, Zhou J. JP1 suppresses proliferation and metastasis of melanoma through MEK1/2 mediated NEDD4L-SP1-Integrin avß3 signaling. Theranostics. 2020; 10(18):8036-8050. PMID: 32724456; PMCID: PMC7381750.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    14. Punganuru SR, Artula V, Zhao W, Rajaei M, Deokar H, Zhang R, Buolamwini JK, Srivenugopal KS, Wang W. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action. Cells. 2020 Jul 01; 9(7). PMID: 32630235; PMCID: PMC7408354.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    15. Wang W, Zafar A, Rajaei M, Zhang R. Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy. Cells. 2020 05 09; 9(5). PMID: 32397368; PMCID: PMC7291050.
      Citations: 7     Fields:    Translation:HumansAnimals
    16. Wang W, Hu B, Qin JJ, Cheng J, Li X, Rajaei M, Fan J, Yang XR, Zhang R. Corrigendum to "A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance" [Genes Dis 694 (2019) 419-430]. Genes Dis. 2020 03; 7(1):160-161. PMID: 32181287; PMCID: PMC7063448.
      Citations:    
    17. Wang W, Qin JJ, Rajaei M, Li X, Yu X, Hunt C, Zhang R. Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev. 2020 05; 40(3):856-880. PMID: 31587329; PMCID: PMC7131869.
      Citations: 41     Fields:    Translation:HumansAnimals
    18. Wang W, Hu B, Qin JJ, Cheng JW, Li X, Rajaei M, Fan J, Yang XR, Zhang R. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis. 2019 Dec; 6(4):419-430. PMID: 31832522; PMCID: PMC6889017.
      Citations: 25     
    19. Punganuru SR, Madala HR, Arutla V, Zhang R, Srivenugopal KS. Characterization of a highly specific NQO1-activated near-infrared fluorescent probe and its application for in vivo tumor imaging. Sci Rep. 2019 Jun 12; 9(1):8577. PMID: 31189950; PMCID: PMC6562040.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    20. Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019 09 10; 459:156-167. PMID: 31181320; PMCID: PMC6650270.
      Citations: 26     Fields:    Translation:HumansCells
    21. Zhang R. Preface. Curr Cancer Drug Targets. 2019; 19(1):2. PMID: 30672408.
      Citations:    Fields:    
    22. Deokar H, Deokar M, Wang W, Zhang R, Buolamwini JK. QSAR Studies of New Pyrido[3,4-b]indole Derivatives as Inhibitors of Colon and Pancreatic Cancer Cell Proliferation. Med Chem Res. 2018 Dec; 27(11-12):2466-2481. PMID: 31360052; PMCID: PMC6662939.
      Citations: 6     
    23. Wang W, Qin JJ, Voruganti S, Nijampatnam B, Velu SE, Ruan KH, Hu M, Zhou J, Zhang R. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. Cancer Res. 2018 10 01; 78(19):5656-5667. PMID: 30217928; PMCID: PMC6435280.
      Citations: 27     Fields:    Translation:AnimalsCells
    24. Wang W, Qin JJ, Li X, Tao G, Wang Q, Wu X, Zhou J, Zi X, Zhang R. Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis. 2018 07 30; 39(8):1026-1036. PMID: 29762656; PMCID: PMC6067121.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    25. Qin JJ, Li X, Hunt C, Wang W, Wang H, Zhang R. Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes Dis. 2018 Sep; 5(3):204-219. PMID: 30320185; PMCID: PMC6176154.
      Citations: 43     
    26. Qin JJ, Wang W, Li X, Deokar H, Buolamwini JK, Zhang R. Inhibiting ?-Catenin by ?-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Front Pharmacol. 2018; 9:5. PMID: 29387014; PMCID: PMC5776119.
      Citations: 15     
    27. Zhang R. Preface. Curr Cancer Drug Targets. 2018; 18(1):2. PMID: 29517469.
      Citations:    Fields:    Translation:Humans
    28. Madala HR, Punganuru SR, Ali-Osman F, Zhang R, Srivenugopal KS. Brain- and brain tumor-penetrating disulfiram nanoparticles: Sequence of cytotoxic events and efficacy in human glioma cell lines and intracranial xenografts. Oncotarget. 2018 Jan 09; 9(3):3459-3482. PMID: 29423059; PMCID: PMC5790476.
      Citations: 21     Fields:    
    29. Qin JJ, Li X, Wang W, Zi X, Zhang R. Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Front Pharmacol. 2017; 8:917. PMID: 29311926; PMCID: PMC5735069.
      Citations: 21     
    30. Li X, Ba Q, Liu Y, Yue Q, Chen P, Li J, Zhang H, Ying H, Ding Q, Song H, Liu H, Zhang R, Wang H. Dihydroartemisinin selectively inhibits PDGFRa-positive ovarian cancer growth and metastasis through inducing degradation of PDGFRa protein. Cell Discov. 2017; 3:17042. PMID: 29387451; PMCID: PMC5787695.
      Citations: 22     
    31. Qin JJ, Wang W, Zhang R. Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1-MDM2-p53 Pathway. Prog Mol Biol Transl Sci. 2017; 151:195-216. PMID: 29096894; PMCID: PMC6663080.
      Citations: 11     Fields:    Translation:HumansCells
    Zhang's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (129)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _